Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
With a market cap of 9.59B, Moderna(MRNA) trades at $24.46. The stock has a price-to-earnings ratio of -3.04.
On 2025-11-07, Moderna(MRNA) stock traded between a low of $23.40 and a high of $24.57. Shares are currently priced at $24.46, which is +4.5% above the low and -0.4% below the high.
Moderna(MRNA) shares are trading with a volume of 10.38M, against a daily average of 15.51M.
During the past year, Moderna(MRNA) stock moved between $23.04 at its lowest and $50.90 at its peak.
During the past year, Moderna(MRNA) stock moved between $23.04 at its lowest and $50.90 at its peak.
MRNA News
Morgan Stanley lowered the firm’s price target on Moderna (MRNA) to $30 from $32 and keeps an Equal Weight rating on the shares. Meet Your ETF AI Analyst Disc...
Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Meet Your ETF AI Analyst Discover...
Moderna ((MRNA)) has held its Q3 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can...
Analyst ratings
59%
of 27 ratingsMore MRNA News
Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the December 26th expiration. At Stock Options Channel , our YieldBoost formula...
(RTTNews) - Moderna (MRNA) posted a third-quarter net loss of $200 million compared to net income of $13 million, last year. Loss per share was $0.51 compared t...
Moderna (MRNA) stock jumped early Thursday after the biotech company reported a loss of 51 cents per share on $1.02 billion in third-quarter sales. On average,...
Moderna (MRNA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $0.03 per...
Moderna rose in premarket trading after it reported third-quarter results that crushed Wall Street estimates. The company reported a loss per share of $0.51, s...
Moderna (MRNA) drew attention after announcing it had dosed the first patient in a Phase 1/2 trial of mRNA-2808, its experimental T-cell engager for relapsed or...
Moderna (MRNA) is scheduled to announce Q3 earnings results on November 6, before market open, with analysts’ consensus pointing to another quarter of losses....
